Update: See our article discussing notable points from the Draft Guidelines.
Following its Phase 2 Consultations, on December 19, 2024, the Patented Medicine Prices Review Board (PMPRB) released its new Draft Guidelines and accompanying Overview. The deadline for providing submissions on the Draft Guidelines is March 19, 2025. The PMPRB continues to plan to release its final Guidelines in 2025.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
pCPA introducing revisions to pathway for non-complex drug negotiations
The pan-Canadian Pharmaceutical Alliance (pCPA) recently announced it is formalizing and introducing revisions to the Targeted Negotiation Process (TNP).Read More -
Ontario proposes legislation to regulate preferred provider networks
Following two public consultations with stakeholders, the Government of Ontario (Ministry of Finance) is moving forward with legislation to regulate preferred provider networks (PPNs).Read More -
Canada’s Drug Agency releases new resource and data on drug approval and reimbursement pathway
Canada’s Drug Agency (CDA-AMC) published data on Canada’s drug system as part of the Data Systems and Analytics program.Read More
